- Home
- NRBO vs KALA Comparison
NRBO vs KALA Comparison
Compare NRBO & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRBO
- KALA
- Stock Information
- Founded
- NRBO N/A
- KALA 2009
- Country
- NRBO United States
- KALA United States
- Employees
- NRBO N/A
- KALA N/A
- Industry
- NRBO Biotechnology: Pharmaceutical Preparations
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- NRBO Health Care
- KALA Health Care
- Exchange
- NRBO Nasdaq
- KALA Nasdaq
- Market Cap
- NRBO 27.9M
- KALA 32.0M
- IPO Year
- NRBO N/A
- KALA 2017
- Fundamental
- Price
- NRBO $2.42
- KALA $6.58
- Analyst Decision
- NRBO Strong Buy
- KALA Strong Buy
- Analyst Count
- NRBO 1
- KALA 2
- Target Price
- NRBO $10.00
- KALA $15.00
- AVG Volume (30 Days)
- NRBO 36.9K
- KALA 33.2K
- Earning Date
- NRBO 11-07-2024
- KALA 11-12-2024
- Dividend Yield
- NRBO N/A
- KALA N/A
- EPS Growth
- NRBO N/A
- KALA N/A
- EPS
- NRBO N/A
- KALA N/A
- Revenue
- NRBO N/A
- KALA N/A
- Revenue This Year
- NRBO N/A
- KALA N/A
- Revenue Next Year
- NRBO N/A
- KALA N/A
- P/E Ratio
- NRBO N/A
- KALA N/A
- Revenue Growth
- NRBO N/A
- KALA N/A
- 52 Week Low
- NRBO $2.08
- KALA $4.21
- 52 Week High
- NRBO $6.75
- KALA $10.97
- Technical
- Relative Strength Index (RSI)
- NRBO 40.83
- KALA 49.93
- Support Level
- NRBO $2.30
- KALA $6.00
- Resistance Level
- NRBO $2.50
- KALA $7.85
- Average True Range (ATR)
- NRBO 0.23
- KALA 0.40
- MACD
- NRBO -0.01
- KALA -0.11
- Stochastic Oscillator
- NRBO 24.75
- KALA 29.19
About NRBO NeuroBo Pharmaceuticals Inc.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.